Article

#17: Gene Therapy and its Potential in Macular Degeneration

Gene therapy first hit the radar of retinal physicians in 2008, when three independent research groups reported that patients with Leber's congenital amaurosis, a rare genetic retinal disease, had been successfully treated using gene therapy with adeno-associated virus (AAV).

Gene therapy first hit the radar of retinal physicians in 2008, when three independent research groups reported that patients with Leber's congenital amaurosis, a rare genetic retinal disease, had been successfully treated using gene therapy with adeno-associated virus (AAV).

Since then, a host of researchers have begun to explore the potential use of gene therapy in, among other conditions, age-related macular degeneration (AMD). Current research is primarily focused on cutting down the current need for frequent administration of an anti-vascular endothelial growth-factor (VEGF) agent to just a single, subretinal injection.

Gene therapy is a promising area of ongoing research in patients with macular degeneration.

Gene therapy is not, as often misconstrued, limited to the treatment of genetic diseases, but is rather a treatment modality in which genetic material is introduced into cells, either to compensate for an abnormal gene or to make a beneficial protein. Current gene therapy trials in AMD focus on this second area.

A handful of phase I gene therapy trials of VEGF-binding proteins were completed with promising results in small numbers of patients with AMD. However, results from a phase II trial reported in July 2015 of Avalanche Biosciences' AVA-101 in wet AMD have stemmed a bit of the momentum. In that trial, while the primary endpoint of safety (as determined by number of complications at 1 year vs. placebo) was met, results from secondary efficacy goals such as visual acuity and reducing retinal thickness were not as impressive. Based on these results, a planned phase IIB trial was halted.

Nonetheless, several additional phase II trials testing other gene therapy technologies have recently opened to enrollment. Two of these trials are focusing on cell therapy for atrophic AMD while a third is focused on patients with geographic atrophy secondary to AMD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.